CRDF
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Cardiff Oncology, Inc.
- Nom
- Cardiff Oncology, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $70.6M
- Employés
- 31
- PDG
- Mani Mohindru
- Site web
- https://www.cardiffoncology.com
- Marché
- APLTCRBPELTXFBRXIPHAMIST
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 721649 titres (~959793 USD)
- Insiders
- Mohindru ManiPACE GARY W
- Total bought
-
$959,793
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-14
- Last synced
-
2026-10-19 22:07:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
CRDF presents a critically weak financial profile — persistent operating losses, high cash burn, and no meaningful revenue growth — that is not offset by a diluted catalyst signal.
The first sentence of the analysis written for CRDF on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 3.67 · operating margin -8256% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Ebitda Margin | -7579.6% | -6592.5% | -8410.5% | -9965.8% | -7754.9% | |
| Operating Profit Margin | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -8037.6% | |
| Pretax Profit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Continuous Operations Profit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Net Profit Margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | |
| Bottom Line Profit Margin | -7736.3% | -6655.2% | -8496.9% | -10033.2% | -7887.2% | |
| Current Ratio | 3.668 | 7.079 | 7.415 | 14.253 | 22.279 | |
| Quick Ratio | 3.668 | 7.079 | 7.415 | 14.253 | 22.279 | |
| Solvency Ratio | -2.725 | -3.162 | -3.450 | -3.906 | -3.050 | |
| Cash Ratio | 1.066 | 3.833 | 2.074 | 2.094 | 1.821 | |
| Price To Earnings Ratio | -4.072 | -4.568 | -1.591 | -1.573 | -8.233 | |
| Price To Earnings Growth Ratio | 0.149 | -2.124 | -0.354 | -0.072 | 0.254 | |
| Forward Price To Earnings Growth Ratio | 0.149 | -2.124 | -0.354 | -0.072 | 0.254 | |
| Price To Earnings Diluted Ratio | -4.072 | -4.568 | -1.591 | -1.573 | -8.233 | |
| Price To Earnings Diluted Growth Ratio | 0.149 | -2.124 | -0.354 | -0.072 | 0.254 | |
| Price To Book Ratio | 4.138 | 2.493 | 0.948 | 0.574 | 1.671 | |
| Price To Sales Ratio | 316.734 | 302.783 | 135.496 | 158.135 | 653.399 | |
| Price To Free Cash Flow Ratio | -4.947 | -5.475 | -2.101 | -1.758 | -10.091 | |
| Price To Operating Cash Flow Ratio | -4.953 | -5.486 | -2.141 | -1.805 | -10.181 | |
| Debt To Assets Ratio | 0.013 | 0.016 | 0.026 | 0.023 | 0.021 | |
| Debt To Equity Ratio | 0.018 | 0.018 | 0.031 | 0.026 | 0.022 | |
| Debt To Capital Ratio | 0.018 | 0.018 | 0.030 | 0.025 | 0.022 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.363 | 1.172 | 1.171 | 1.093 | 1.065 | |
| Working Capital Turnover Ratio | 0.009 | 0.009 | 0.006 | 0.003 | 0.003 | |
| Operating Cash Flow Ratio | -2.313 | -2.807 | -2.959 | -4.331 | -3.513 | |
| Operating Cash Flow Sales Ratio | -63.951 | -55.187 | -63.293 | -87.617 | -64.178 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.002 | 1.019 | 1.026 | 1.009 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -45.581 | -24.749 | -14.373 | -12.457 | -7.387 | |
| Capital Expenditure Coverage Ratio | -861.886 | -471.163 | -53.070 | -37.915 | -112.390 | |
| Dividend Paid And Capex Coverage Ratio | -861.886 | -471.163 | -53.070 | -25.896 | -100.611 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | -0.011 | -0.001 | |
| Enterprise Value Multiple | -3.809 | -3.484 | -1.136 | -1.232 | -8.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 0.0% |
| Ebit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Ebitda Margin | -7579.6% | ▼-987.1% | ▲481.1% |
| Operating Profit Margin | -8256.3% | ▼-1133.2% | ▲355.7% |
| Pretax Profit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Continuous Operations Profit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Net Profit Margin | -7732.0% | ▼-1080.4% | ▲424.6% |
| Bottom Line Profit Margin | -7736.3% | ▼-1081.1% | ▲425.5% |
| Current Ratio | 3.668 | ▼-3.411 | ▼-7.271 |
| Quick Ratio | 3.668 | ▼-3.411 | ▼-7.271 |
| Solvency Ratio | -2.725 | ▲0.437 | ▲0.534 |
| Cash Ratio | 1.066 | ▼-2.767 | ▼-1.112 |
| Price To Earnings Ratio | -4.072 | ▲0.496 | ▼-0.065 |
| Price To Earnings Growth Ratio | 0.149 | ▲2.273 | ▲0.578 |
| Forward Price To Earnings Growth Ratio | 0.149 | ▲2.273 | ▲0.578 |
| Price To Earnings Diluted Ratio | -4.072 | ▲0.496 | ▼-0.065 |
| Price To Earnings Diluted Growth Ratio | 0.149 | ▲2.273 | ▲0.578 |
| Price To Book Ratio | 4.138 | ▲1.645 | ▲2.173 |
| Price To Sales Ratio | 316.734 | ▲13.951 | ▲3.425 |
| Price To Free Cash Flow Ratio | -4.947 | ▲0.528 | ▼-0.072 |
| Price To Operating Cash Flow Ratio | -4.953 | ▲0.534 | ▼-0.040 |
| Debt To Assets Ratio | 0.013 | ▼-0.002 | ▼-0.006 |
| Debt To Equity Ratio | 0.018 | -0.000 | ▼-0.005 |
| Debt To Capital Ratio | 0.018 | -0.000 | ▼-0.004 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.363 | ▲0.192 | ▲0.191 |
| Working Capital Turnover Ratio | 0.009 | ▲0.000 | ▲0.003 |
| Operating Cash Flow Ratio | -2.313 | ▲0.494 | ▲0.871 |
| Operating Cash Flow Sales Ratio | -63.951 | ▼-8.764 | ▲2.894 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.001 | ▼-0.010 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -45.581 | ▼-20.831 | ▼-24.671 |
| Capital Expenditure Coverage Ratio | -861.886 | ▼-390.724 | ▼-554.601 |
| Dividend Paid And Capex Coverage Ratio | -861.886 | ▼-390.724 | ▼-559.361 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▲0.002 |
| Enterprise Value Multiple | -3.809 | ▼-0.325 | ▼-0.255 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $187.8M | $206.8M | $66.1M | $61.0M | $234.6M | |
| Enterprise value | $171.2M | $156.9M | $46.6M | $47.4M | $225.7M | |
| EV / Sales | 288.68x | 229.65x | 95.53x | 122.82x | 628.82x | |
| EV / Op. cash flow | -4.51x | -4.16x | -1.51x | -1.40x | -9.80x | |
| EV / Free cash flow | -4.51x | -4.15x | -1.48x | -1.37x | -9.71x | |
| EV / EBITDA | -3.81x | -3.48x | -1.14x | -1.23x | -8.11x | |
| Net debt / EBITDA | 0.37x | 1.11x | 0.47x | 0.35x | 0.32x | |
| Current ratio | 3.67x | 7.08x | 7.42x | 14.25x | 22.28x | |
| Income quality | 0.83x | 0.83x | 0.74x | 0.87x | 0.81x | |
| Graham net-net | $1 | $2 | $1 | $2 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $43.7M | $81.6M | $67.0M | $103.5M | $139.6M | |
| Invested capital | $44.9M | $83.7M | $69.9M | $107.0M | $142.7M | |
| Return on assets | -74.1% | -46.7% | -50.8% | -33.3% | -18.9% | |
| Operating ROA | -61.6% | -54.4% | -45.9% | -30.0% | -20.3% | |
| Return on tangible assets | -74.1% | -46.7% | -50.8% | -33.3% | -18.9% | |
| Return on equity | -101.0% | -54.8% | -59.4% | -36.4% | -20.1% | |
| Return on invested capital | -105.9% | -57.6% | -63.2% | -36.6% | -20.1% | |
| Return on capital employed | -107.6% | -58.1% | -63.8% | -36.8% | -20.2% | |
| Earnings yield | -24.4% | -22.0% | -62.7% | -63.4% | -12.1% | |
| Free cash flow yield | -20.2% | -18.3% | -47.6% | -56.9% | -9.9% | |
| Capex / Op. cash flow | -0.1% | -0.2% | -1.9% | -2.6% | -0.9% | |
| Capex / Depreciation | 4.9% | 19.8% | 146.2% | 378.0% | 45.5% | |
| Capex / Sales | 7.4% | 11.7% | 119.3% | 231.1% | 57.1% | |
| SG&A / Sales | 2398.7% | 1827.5% | 2672.7% | 3414.8% | 3297.5% | |
| R&D / Sales | 5957.7% | 5395.6% | 6733.0% | 7022.5% | 4840.1% | |
| Stock comp / Sales | 960.0% | 696.9% | 924.0% | 1102.6% | 900.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 112d | 413d | 215d | 729d | 544d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 112d | 413d | 215d | 729d | 544d | |
| Cash conversion cycle | 112d | 413d | 215d | 729d | 544d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-21 Financial Contrast: Monte Rosa Therapeutics (NASDAQ:GLUE) & Cardiff Oncology (NASDAQ:CRDF) Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Insider and Institutional Ownership 80.0% of
- 2026-09-14 Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l.
- 2026-09-02 Cardiff Oncology to Participate in September 2026 Conferences SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
- 2026-08-11 Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC